Prospective study evaluating aflibercept in patients with recurrent or prolonged diabetic macular edema after vitrectomy

Trial Profile

Prospective study evaluating aflibercept in patients with recurrent or prolonged diabetic macular edema after vitrectomy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2016 Planned End Date changed from 1 Feb 2017 to 31 Mar 2019.
    • 13 Feb 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.
    • 06 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top